Sprint Bioscience wins Vinnova grant of about SEK 940,000 for MAX IV fragment screening project

Bitget2026/10/01 08:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sprint Bioscience, MAX IV won about SEK 940,000 from Sweden’s Vinnova for fragment-screening research to support drug discovery.
Sprint may receive up to about SEK 704,000; project runs from November 2026 to October 2028.
Work will compare cryogenic versus room-temperature fragment screening to assess temperature effects on fragment binding to target proteins.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sprint Bioscience AB published the original content used to generate this news brief on October 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sprint Bioscience wins Vinnova grant of about SEK 940,000 for MAX IV fragment screening project

You may also like

Crypto prices